Torisel (Pfizer) fails in combination trial with Avastin in Renal Cell Carcinoma - 12-Aug-2012

Pfizer Inc. announced that the Phase III INTORACT trial (B1771006), evaluating the combination of bevacizumab plus Torisel (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-?-2a) in the first-line treatment of patients with advanced Renal Cell Carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population. Additional efficacy endpoints and safety data for the combination treatments in both arms are being analyzed and will be presented at an upcoming major medical congress.

Related News

Further results from TIVO-1 study of tivozanib (Aveo Oncology/ Astellas) for Renal Cell Carcinoma treatment

IQWiG review of Inlyta(Pfizer),Nexavar (Bayer)and Afinitor (Novartis) as treatments for Renal Cell Carcinoma

NICE rejects Inlyta(Pfizer) for treatment of Renal Cell Carcinoma

Rencarex (WILEX) programme in Renal Cell Carcinoma is cancelled

Inlyta (Pfizer) not superior to Nexavar in Renal Cell Carcinoma trial

Votrient (GSK) is non inferior to Sutent ( Pfizer) in COMPRAZ study for Renal Cell Carcinoma

Aveo files tivozanib at FDA for treatment of Renal Cell Carcinoma

EC approves Inlyta (Pfizer) for Real Cell Carcinoma

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Results positive for Afinitor (Novartis) in BOLERO-3 study in HER2 positive Breast Cancer

19 May 2013

Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced Breast Cancer showed that Afinitor (everolimus) tablets,...

Read full article

Study of Prolia (Amgen/GSK) plus teriparatide shows significant benefits in Osteoporosis

19 May 2013

A randomised, controlled trial of postmenopausal women with Osteoporosis shows that teriparatide and Prolia (denosumab), from Amgen/GSK,...

Read full article